Full text is available at the source.
Abstract
GLP-1 receptor agonists, such as semaglutide, show significant efficacy in lowering glucose and weight with weekly injections.
- Long-acting analogues of incretin hormones demonstrate effectiveness in managing type 2 diabetes and obesity.
- Semaglutide is available in both oral and injectable forms, with ongoing trials for combined therapies.
- Tirzepatide, a dual agonist for GLP-1 and GIP receptors, exhibits particularly high efficacy in glucose and weight reduction.
- Several new peptide therapies, including dual and triagonists targeting multiple receptors, are currently in clinical trials.
- The demand for GLP-1 receptor agonists has created shortages, impacting their availability for type 2 diabetes treatment.
Simplified